Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04099966 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v5
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2020 to Apr 1, 2021
    • Site details revised
    v3
  4. Start date: Oct 1, 2019 to Apr 1, 2020v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mitchell Cairo
1 trial monitored
See all monitored trials
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
Sickle Cell Disease
373 trials monitored
See 23 trials at risk
and 2 more diseases
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Trial Details
NCT Number NCT04099966
Lead Sponsor Mitchell Cairo
Conditions
(from sponsor)		 Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease +1 more
Related terms Anemia, Aplastic, Anemia, Diamond-Blackfan, Anemia, Sickle Cell, beta-Thalassemia, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neutropenia, Severe Congenital, Autosomal Recessive 3
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov